ApoE4 Corrector Binding for Targeted Salt Bridge Disruption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for more apoE4 correctors that are safe and well-tolerated, and specifically bind to apoE4 to induce a structural change mimicking apoE3 or apoE2, addressing the adverse effects associated with apoE4, which are not related to amyloid or beta-amyloid.
Innovation Solution
Tramiprosate and its derivatives, prodrugs, and salts are used to bind directly to apoE4 at a specific site, disrupting the salt bridge between Arg61 and Glu255, inducing an apoE3-like conformation, thereby treating apoE4-related conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If highly hydrophobic small molecules are used as apoE4 correctors, then apoE4 structure correction is achieved, but off-target effects increase and specificity decreases
Solution Approach 1:
The patent introduces an intermediary binding site mechanism where tramiprosate binds to a specific site on apoE4 that is distinct from the amyloid-binding site. This intermediary binding location allows the corrector to disrupt the intramolecular salt bridge between Arg61 and Glu255 without directly competing with amyloid-beta binding, thereby achieving structure correction while minimizing off-target effects on amyloid pathways.
Solution Approach 2:
The patent applies local quality by targeting a specific local region on the apoE4 protein structure - the salt bridge region between Arg61 and Glu255. By focusing the corrective action on this specific local site rather than using broad-spectrum hydrophobic molecules, the invention achieves precise structure correction while avoiding widespread off-target interactions.
2Manufacturing precision
If tramiprosate is used to bind to apoE4, then specific structural change is induced, but the mechanism for non-amyloid conditions needs clarification
Solution Approach 1:
The patent extracts and isolates the specific binding interaction between tramiprosate and the apoE4 salt bridge region from the complex amyloid-related pathways. By separating this structural correction mechanism from amyloid-beta binding activities, the invention clarifies how tramiprosate can correct apoE4 structure independently of amyloid pathways, enabling treatment of non-amyloid apoE4-related conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Tramiprosate effectively alters the apoE4 structure to mimic apoE3, providing therapeutic benefits for conditions associated with apoE4 without involving amyloid or beta-amyloid pathways.
Implementation Method 1
interacts with amino acids Asp107... likely to disrupt the salt bridge between Arg61 and Glu255 that is induced by Arg112
Implementation Method 2
converts apoE4 into an apoE3-like conformation and reverses the apoE4-specific detrimental effects
Data Source
AI summary
Provided herein is the use of tramiprosate, a prodrug of tramiprosate, a tramiprosate analog, a prodrug of a tramiprosate analog, a pharmaceutically acceptable salt of any of the foregoing, or an isotopically enriched form of any of the foregoing for treating an ApoE4-related, non-amyloid disease or condition.